July 8 China venture roundup: Latest financing by Zhiyi brings series B funding to $45M

Guangzhou Zhiyi Biotechnology Co. Ltd. raised an RMB100 million ($14.9 million) series B++ round to advance the development of its live bacteria products. Zhiyi Bio, which has raised RMB300 million in the past 18 months, is targeting indications including irritable bowel syndrome and solid tumors. 

Wuhan Youzhiyou Biopharma Co. Ltd. raised a RMB200 million pre-C round to accelerate the development of its bispecific antibodies and vaccines. Wuhan Hi-Tech, Hubei Technology Investment Group and Optics Valley Financial Holding Group participated in the financing. The company, which was founded by Zhou Pengfei, and has five assets in clinical development. ...